252 related articles for article (PubMed ID: 15668979)
1. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.
Patel NK; Bunnage M; Plaha P; Svendsen CN; Heywood P; Gill SS
Ann Neurol; 2005 Feb; 57(2):298-302. PubMed ID: 15668979
[TBL] [Abstract][Full Text] [Related]
2. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.
Gill SS; Patel NK; Hotton GR; O'Sullivan K; McCarter R; Bunnage M; Brooks DJ; Svendsen CN; Heywood P
Nat Med; 2003 May; 9(5):589-95. PubMed ID: 12669033
[TBL] [Abstract][Full Text] [Related]
3. Crossroads in GDNF therapy for Parkinson's disease.
Sherer TB; Fiske BK; Svendsen CN; Lang AE; Langston JW
Mov Disord; 2006 Feb; 21(2):136-41. PubMed ID: 16470786
[TBL] [Abstract][Full Text] [Related]
4. Research on Parkinson disease.
Slevin JT; Gerhardt GA; Smith CD; Gash DM; Kryscio R; Young B
J Neurosurg; 2005 Feb; 102(2):401. PubMed ID: 15739575
[No Abstract] [Full Text] [Related]
5. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor.
Slevin JT; Gerhardt GA; Smith CD; Gash DM; Kryscio R; Young B
J Neurosurg; 2005 Feb; 102(2):216-22. PubMed ID: 15739547
[TBL] [Abstract][Full Text] [Related]
6. Localized striatal delivery of GDNF as a treatment for Parkinson disease.
Kirik D; Georgievska B; Björklund A
Nat Neurosci; 2004 Feb; 7(2):105-10. PubMed ID: 14747832
[No Abstract] [Full Text] [Related]
7. In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.
Kordower JH
Ann Neurol; 2003; 53 Suppl 3():S120-32; discussion S132-4. PubMed ID: 12666104
[TBL] [Abstract][Full Text] [Related]
8. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys.
Zhang Z; Miyoshi Y; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1396-401. PubMed ID: 9316852
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease.
Lapchak PA; Gash DM; Collins F; Hilt D; Miller PJ; Araujo DM
Exp Neurol; 1997 Jun; 145(2 Pt 1):309-21. PubMed ID: 9217068
[No Abstract] [Full Text] [Related]
10. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
J Neurosurg; 2007 Apr; 106(4):614-20. PubMed ID: 17432712
[TBL] [Abstract][Full Text] [Related]
11. New treatment improves symptoms of Parkinson's disease.
Mayor S
BMJ; 2002 Apr; 324(7344):997. PubMed ID: 11976237
[No Abstract] [Full Text] [Related]
12. GDNF delivery for Parkinson's disease.
Patel NK; Gill SS
Acta Neurochir Suppl; 2007; 97(Pt 2):135-54. PubMed ID: 17691299
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.
Nutt JG; Burchiel KJ; Comella CL; Jankovic J; Lang AE; Laws ER; Lozano AM; Penn RD; Simpson RK; Stacy M; Wooten GF;
Neurology; 2003 Jan; 60(1):69-73. PubMed ID: 12525720
[TBL] [Abstract][Full Text] [Related]
14. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
15. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
Lindvall O; Wahlberg LU
Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
[TBL] [Abstract][Full Text] [Related]
16. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
17. [Growth factors as neuroprotective treatment in Parkinson disease?].
Torp R; Singh PB; Sørensen DR; Dietrichs E; Hirschberg H
Tidsskr Nor Laegeforen; 2006 Mar; 126(7):899-901. PubMed ID: 16554879
[TBL] [Abstract][Full Text] [Related]
18. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.
Winkler C; Georgievska B; Carlsson T; Lacar B; Kirik D
Neuroscience; 2006 Aug; 141(1):521-31. PubMed ID: 16697115
[TBL] [Abstract][Full Text] [Related]
19. Reoperation for suboptimal outcomes after deep brain stimulation surgery.
Ellis TM; Foote KD; Fernandez HH; Sudhyadhom A; Rodriguez RL; Zeilman P; Jacobson CE; Okun MS
Neurosurgery; 2008 Oct; 63(4):754-60; discussion 760-1. PubMed ID: 18981887
[TBL] [Abstract][Full Text] [Related]
20. MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF).
Chebrolu H; Slevin JT; Gash DA; Gerhardt GA; Young B; Given CA; Smith CD
Exp Neurol; 2006 Apr; 198(2):450-6. PubMed ID: 16455079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]